Advances in neonatal care have improved the survival of extremely preterm infants. Chronic lung disease (CLD) is a common complication of prematurity, seen in about a third of preterm babies. Further, pulmonary hypertension complicates the hospital course in about 18% of preterm infants, and the incidence is much higher in infants with established CLD. There is increasing interest in studying this population and understanding the underlying pathobiology behind the development of pulmonary hypertension, which could lead to better identification of at-risk patients as well as improved management strategies and therapeutic targets.
INTRODUCTION
Chronic lung disease of infancy (CLD), formerly known as bronchopulmonary dysplasia (BPD), is an important cause of morbidity and mortality in preterm neonates [1 && ]. Despite improvements in respiratory management and care for these vulnerable infants, the prevalence of BPD has not changed significantly, occurring in 25-38% of premature newborns [2 & ,3]. There is, however, a difference in the lung disease in the extremely preterm infants surviving in the modern era. Abman and others have categorized this as the 'New BPD,' which is characterized by defects in angiogenesis and alveolarization as opposed to the 'old BPD,' which was associated with extensive inflammation, cystic emphysema and fibrosis secondary to aggressive ventilation and other postnatal insults [4,5 && ]. Pulmonary hypertension has been reported to be associated with CLD in nearly 20% of extremely preterm babies overall, and in 50% of those with severe chronic lung disease [5 && ,6] . Pulmonary hypertension in association with CLD has been reported to have a 2-year mortality rate of 48% [7] . Though pulmonary vasodilator medications are often used in these infants, there are no large controlled studies evaluating their efficacy and safety, and the medications are used 'off label,' based on experience in adults with idiopathic pulmonary arterial hypertension and other forms of 'Group 1' pulmonary arterial hypertension. Recurrent insults to the growing lung lead to the establishment of CLD, and also changes to the pulmonary vasculature and endothelium. Acute pulmonary vasoreactivity leading to pulmonary hypertension crises may also be seen during inflammatory or infectious lung insults, and the degree of pulmonary hypertension detected may be variable depending on the timing of the evaluation [8 & ,9] . It is necessary to develop a standard algorithm for screening and follow-up of infants with CLD, to diagnose and manage pulmonary hypertension appropriately.
EPIDEMIOLOGY OF PULMONARY HYPERTENSION IN CHRONIC LUNG DISEASE
There are several recent studies describing the epidemiology of pulmonary hypertension in preterm infants. In a prospective study to determine the prevalence of pulmonary hypertension in a cohort of 145 extremely low-birth-weight infants by echocardiographic screening, Bhat et al. [8 & ] noted pulmonary hypertension in 6% of babies at 4 weeks of age and 12% at a later timepoint. They found that in addition to CLD, a lower birthweight and intrauterine growth restriction correlated with pulmonary hypertension. In that cohort, the presence of pulmonary hypertension significantly impacted length of stay as well as mortality. In a retrospective study utilizing the NICHD neonatal research network database, Slaughter et al. identified pulmonary hypertension in 37% of infants with CLD with a fivefold increase in mortality if pulmonary hypertension was diagnosed on an echocardiogram. Khemani et al. in 2007 [7] reported a mortality of 38% in 42 infants with CLD and pulmonary hypertension, and noted an improvement in the degree of pulmonary hypertension in 89% of survivors. Interestingly, these authors also noted that severe pulmonary hypertension was the only independent predictor of mortality; severity of lung disease did not impact survival. Most studies note improvement in the degree of pulmonary hypertension in the survivors as they grow older, and this follows the improvement in parenchymal lung disease and respiratory support requirements [7] . In a singlecenter study from South Korea, An et al. [10] observed pulmonary hypertension in 25% of 116 infants with BPD. They noted that pulmonary hypertension occurred at a median age of 65 days and correlated with severity of BPD, lower birth weight, long-term ventilator care, oxygenation and presence of a patent ductus arteriosus. On follow-up, there was an improvement of pulmonary hypertension in 76% infants and death in 14%.
PATHOPHYSIOLOGY OF PULMONARY HYPERTENSION IN CHRONIC LUNG DISEASE
Multiple factors are implicated in the development of pulmonary hypertension in CLD. Maternal factors that lead to preterm birth and contribute to CLD include preeclampsia, chorioamnionitis, maternal smoking, alcohol and drug use, antiphospholipid syndrome, intrauterine growth retardation and genetic abnormalities [11, 12] . Postnatal associations with CLD include prolonged ventilation and oxygen exposure, respiratory infection as well as other inflammatory processes, sepsis, persistent patency of the patent ductus arteriosus and fluid overload. The clinical course of extremely preterm infants in the neonatal unit is often complicated by multiple insults, which include ventilator-associated lung and airway infections and inflammation, atelectasis and aspiration pneumonias. Extremely low-birthweight infants have arrested lung development, both in terms of angiogenesis and alveolar simplification [9] . There is decreased cross-sectional area for pulmonary blood flow, leading to increased resistance. This also results in reduced vascular surface for gas exchange. Parenchymal lung disease, infection and atelectasis worsen the hypoxia, causing pulmonary vasoconstriction. Over time, this leads to chronic changes in the pulmonary vasculature, with intimal thickening, formation of plexiform lesions and an increase in smooth muscle cell proliferation. This leads to back pressure changes on the right ventricle and subsequent right ventricular dilatation, hypertrophy and eventually reduced right ventricular function, especially during pulmonary hypertension crises.
Studies of the lungs of preterm infants subjected to prolonged ventilation and oxygen therapy have shown an imbalance of proangiogenic gene products such as vascular endothelial growth factor and antiangiogenic gene products such as endoglin, with a reduction of expression in the former, leading to disruption of angiogenesis [13] . Upregulation of endothelin-1, a known therapeutic target in other forms of pulmonary arterial hypertension, has been
KEY POINTS
Pulmonary hypertension in the presence of CLD is associated with higher mortality.
Early pulmonary hypertension may precede and contribute to prolonged ventilation needs and CLD.
Further studies are needed to evaluate the safety and efficacy of targeted therapies in the management of pulmonary hypertension in CLD.
implicated in neonatal pulmonary hypertension in association with congenital diaphragmatic hernia, as well as in prematurity [14, 15] . Ratner et al. have shown that pulmonary mitochondrial dysfunction leads to delayed alveolarization secondary to mechanical ventilation and hyperoxia in neonatal mice [16, 17] . Several studies have suggested the presence of intrapulmonary arteriovenous anastomotic vessels that open in infants with CLD leading to deoxygenated blood shunting to the pulmonary veins causing hypoxemia. Animal models have shown that intrauterine infection and inflammation modulate pulmonary vascular development [7] . It is possible that these factors may also impact the pulmonary vasculature postnatally. A recent report by Heching et al. [18] explored the relationship between pulmonary vein stenosis and necrotizing enterocolitis. The authors postulate that there may be a relationship between gut inflammation and the postnatal development of pulmonary vein stenosis in ex-preterm infants. There could be a role of circulating smooth muscle cell progenitors or tryosine kinase-related endothelial proliferation triggered by the inflammation. Pulmonary vein stenosis leads to increased back pressure in the pulmonary capillary bed and may also result in pulmonary arteriolar hypertension.
DIAGNOSIS AND SCREENING
It is well established that pulmonary hypertension increases the mortality in patients with BPD four to five-fold. It is important to screen and identify the presence of pulmonary hypertension in these babies. Though cardiac catheterization is considered the gold standard for the diagnosis of pulmonary hypertension, it is generally not feasible to perform diagnostic catheterization at the time pulmonary hypertension is suspected in a preterm infant because of the critical nature of the infant's illness. Clinical monitoring of pre and postductal saturations, as well as charting saturation gradients during routine care, provides very valuable information about the pulmonary vascular status of these infants. It is important to understand that because of significant pulmonary vascular reactivity, the estimates of pulmonary hypertension vary depending on the clinical status, presence of infection or other stressors and pulmonary hypertension 'triggers' at the time of the echocardiogram. The procedure itself can be a stressor, especially in a baby with labile hemodynamics; a previous left to right shunt may reverse at the time of the study. Anesthesia during cardiac catheterization may mask the lability of the pulmonary vasculature and underestimate the severity of pulmonary hypertension during waking and handling of these tiny infants. Thus, an echocardiogram, along with clinical assessment, should be used in infants for whom the risk of cardiac catheterization may outweigh the near-term benefits. If the infant requires long-term targeted pulmonary vasodilator therapy or does not respond as expected to the therapy, then a cardiac catheterization should be strongly considered. In cases in which cardiac catheterization is considered too high risk, echocardiography is of value to establish the presence of elevated right-sided pressures, look for the cause of pulmonary hypertension, rule out associated shunt lesions, diagnose right ventricular systolic or diastolic dysfunction and evaluate the effect of intervention.
It is widely acknowledged that echocardiographic measures may not correlate very well with hemodynamic data obtained during cardiac catheterization. Mourani et al. [19] in a study of 25 children under 2 years of age with BPD, concluded that compared with cardiac catheterization measurements, echocardiographic estimates of systolic pulmonary artery pressure diagnosed correctly the presence or absence of pulmonary hypertension in 79% of the studies, but determined the severity of pulmonary hypertension correctly in only 47% of those studies. However, in a recent elegant prospective study to evaluate early pulmonary disease in preterm infants, the same authors performed echocardiography at 7 days of age and at 36 weeks post conceptional age [7] . They concluded that early pulmonary hypertension correlated with subsequent severity of lung disease, need for ventilation and development of late pulmonary hypertension. It was also associated with a higher mortality. They acknowledge that it is often not possible to perform cardiac catheterization in these vulnerable infants, and used broader echocardiographic criteria for pulmonary hypertension, including: an estimated right ventricularsystolic pressure (RVSP) higher than 40 mmHg, RVSP/systemic systolic blood pressure >0.5, cardiac shunt with bidirectional or right-to-left flow, or any degree of ventricular septal wall flattening. The timing of echocardiogram has been variable in different studies, and there is no consensus on the appropriate time for screening preterm babies for pulmonary hypertension [20 && ]. Figure 1 is a proposed algorithm for the evaluation of pulmonary hypertension in preterm infants.
Cardiac catheterization and computed tomography scans
Despite the concerns regarding cardiac catheterization studies in very sick infants with CLD and pulmonary hypertension detailed above, it is important to evaluate the hemodynamics prior to starting therapy in relatively stable infants. In patients too sick to undergo general anesthesia, computed tomography (CT)/MRI scanning may be a quicker method to determine whether there are associated cardiac abnormalities as well as evaluate the extent of lung parenchymal disease. Del Cerro et al. performed cardiac catheterization in 14 and CT scans in 21 infants with BPD. Hemodynamic data revealed significantly elevated pulmonary artery pressures (median 78% systemic pressure), elevated pulmonary vascular resistance index and elevated left ventricular end diastolic pressure suggesting a degree of left ventricular diastolic dysfunction. They found cardiovascular anomalies in two-thirds of the infants (19/29) including aortopulmonary collaterals (9), pulmonary vein stenosis (7) , patent ductus arteriosus (9) and atrial septal defect (5) , which permitted subsequent therapeutic interventions in many of the patients. These findings are similar to other studies [19,20 && ]. Based on these findings, the authors propose a 1-2 monthly screening for pulmonary hypertension (Fig. 2) [20 && ] in the presence of moderate-tosevere CLD.
TREATMENT

It is very important to treat correctible factors in infants with CLD and pulmonary hypertension.
Ventilation techniques to avoid continued lung injury, and the maintenance of arterial pH and oxygen saturations close to normal, to avoid vasoconstriction from hypoxia or acidosis, are both important. The treatment of reflux, surveillance and early treatment of infections, immunotherapy against viral infections and management of other complications of prematurity including sepsis and necrotizing enterocolitis are key. Surveillance and diagnosis or pulmonary vein stenosis are vital, as the use of pulmonary vasodilators in the presence of significant pulmonary vein stenosis can lead to pulmonary edema. The use of diuretics, steroids and bronchodilators may be of value in selected infants.
TARGETED THERAPY
Inhaled nitric oxide (iNO) is often used in babies who have very labile hemodynamics secondary to pulmonary hypertension crises. The maximum dose usually does not exceed 20 parts per million (PPM), and the medication is weaned when feasible. Weaning protocols differ between institutions; however, it is common experience that the last 3-5 PPM of iNO is difficult to wean because of rebound pulmonary hypertension, and strategies to prevent deterioration include increasing the fraction of inhaled oxygen (FiO 2 ) and the use of sildenafil to prevent rebound pulmonary hypertension [21] . There are animal studies suggesting the effectiveness of sildenafil in improving vascular remodeling and angiogenesis [22,23 & ]. Pulmonary vasodilators also cause systemic vasodilation and hence it is important to monitor systemic blood pressure during use. None of the targeted pulmonary hypertension medications are approved for use in children aside from iNO. Though sildenafil is the medication most commonly used in neonatal units for pulmonary hypertension associated with CLD, one must be aware of the potential side-effects. The side-effects common to all targeted pulmonary hypertension medications include systemic vasodilation, leading to hypotension, flushing and transient rashes. Systemic vasodilation is also associated with headaches in older patients, and infants may manifest Chronic lung disease and pulmonary hypertension Krishnan and Rosenzweig the same with increasing irritability. Nasal congestion and occasionally airway hyperreactivity may be seen in older patients. These side-effects may occur in infants with CLD who have critical airways and manifest as further worsening of airway congestion and 'BPD spells,' wherein there may be poor air entry and chest movement because of upper airway obstruction. The presence of tracheomalacia or bronchomalacia, as occurs in Down syndrome, may worsen these symptoms. As systemically given pulmonary vasodilators cause generalized pulmonary vasodilation, they may also cause ventilation perfusion mismatch and a fall in oxygen saturations. Worsening gastroesophageal reflux is also associated with the use of these medications.
There are several case reports describing the use of sildenafil, bosentan, inhaled prostanoids and subcutaneous prostanoids in this population with encouraging results; however, there are no controlled studies describing their effectiveness. Recently, the Food and Drug administration issued a black box warning against the use of sildenafil in children aged 1-17 years, based on the results of the STARTS-1 study. This international study using low, medium and high-dose sildenafil in treatment-naïve children found an increased association between high-dose sildenafil and mortality [24, 25] . However, this study did not include infants. After this warning, a group of experts in pulmonary hypertension discussed the implications of suddenly withdrawing sildenafil use in children with pulmonary hypertension and suggested physician judgment in using low-dose sildenafil in doses recommended by the European Medicines Agency [26] . Subcutaneous treprostinil has been shown to be well tolerated and efficacious in small case series of infants with CLD and has been shown to be not associated with significant pain [27, 28] . Thus, any of these targeted agents should only be used by a team familiar with their use and potential side-effects.
CONCLUSION
Pulmonary hypertension is frequently diagnosed in infants with CLD and is associated with significant morbidity and mortality. Screening for the early development of pulmonary hypertension, as well as periodic screening with established CLD, will help diagnose pulmonary hypertension and allow early treatment if indicated. Other studies, including CT scanning and cardiac catheterization, are important to rule out associated conditions and assess disease severity and response to vasodilators. The management of infants with pulmonary hypertension and CLD includes supportive measures and avoidance of pulmonary hypertension triggers, as well as possible targeted pulmonary vasodilator therapy with close monitoring.
